Quest Diagnostics: Q2 Earnings Insights

Shares of Quest Diagnostics DGX moved higher by 0.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 17.92% year over year to $1.42, which beat the estimate of $1.41.

Revenue of $1,827,000,000 decreased by 6.45% from the same period last year, which beat the estimate of $1,520,000,000.

How To Listen To The Conference Call

Date: Jul 23, 2020

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.questdiagnostics.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2403389&sessionid=1&key=27104880DA863D0429FD44824A7CE4E7&regTag=&sourcepage=register

Price Action

Company's 52-week high was at $129.82

52-week low: $73.02

Price action over last quarter: Up 31.13%

Company Profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of 2,000 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.